Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058071 · ClinicalTrials.gov registry record · Phase 3
Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
A Phase 3 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00058071 is a Phase 3 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 100 participants.
The verdict
NCT00058071, a Phase 3 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
RATIONALE: Amifostine may be effective in relieving numbness, tingling, and other symptoms of peripheral neuropathy. It is not yet known whether amifostine is effective in treating peripheral neuropathy in patients who have received chemotherapy for cancer. PURPOSE: This randomized phase III trial is studying amifostine to see how well it works compared to observation in relieving numbness, tingling, and other symptoms of peripheral neuropathy in patients who have received platinum-based chemotherapy (such as cisplatin or carboplatin) for cancer.
Interventions
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058071
The ClinicalTrials.gov registry entry for NCT00058071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which amifostine trihydrate is the first listed.
NCT00058071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058071 about?
NCT00058071 is a clinical study titled "Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer". RATIONALE: Amifostine may be effective in relieving numbness, tingling, and other symptoms of peripheral neuropathy. It is not yet known whether amifostine is effective in treating peripheral neuropathy in patients who have received chemotherapy for cancer. PURPOSE: This randomized phase III trial ...
What is the current status of trial NCT00058071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2003-03.
What interventions are being tested in trial NCT00058071?
The interventions under investigation include: amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00058071?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.